Last updated on September 2018

Extramedullary Leukemia (EML) in Newly Diagnosed Acute Myeloid Leukemia (AML) is Underreported


Brief description of study

The goal of this clinical research study is to learn if positron emission tomography/magnetic resonance imaging (PET/MRI), positron emission tomography/computed tomography (PET/CT) and whole body magnetic resonance imaging (MRI) can be used to detect extramedullary myeloid leukemia (EML). EML is a type of cancer found outside of the bone marrow and can be hard to detect with routine bone marrow monitoring, such as bone marrow aspirations.

This is an investigational study. The PET/MRI and PET/CT scans on this study are performed using FDA-approved and commercially available methods. Using these scans to detect EML is considered investigational.

Up to 55 participants will be enrolled on this study. All will take part at MD Anderson..

Detailed Study Description

If you choose to take part in this study, you will have a PET/MRI and PET/CT scan before you start your regular treatment.

When you arrive at the clinic for your PET/MRI-PET/CT scans, you will receive a "radioisotope" and a "contrast" solutions by vein to make the images more accurate. If you feel very nervous, the doctor may give you medication to help calm you down.

You will have the PET/MRI scan, for which you will have to lie on a table in the scanner for about an hour. In a different room, you have a PET/CT scan, for which you will have to lie on a table in the scanner for about 30 minutes.

You and your regular doctor will be told if anything unusual is found in your scans, and the information will be put in your medical record.

Information will also be collected from your medical record for at least 1 year after you complete the scans.

Clinical Study Identifier: NCT02390635

Contact Investigators or Research Sites near you

Start Over

Vikas Kundra, MD, PHD

University of Texas MD Anderson Cancer Center
Houston, TX United States
  Connect »